AMIX Stock Catalyst: Autonomix Medical Granted European Patent for Nerve-Targeted Cardiology Platform

Dec 29, 2025 · 7:16pm ET

The patent enables precision therapies in cardiology.

Max move

+71.0%

High of day $18.90

Sparker timei

7:16pm ET

AMIX · Dec 29, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Autonomix Medical, Inc. (AMIX) announced on December 30, 2025, that it has been granted a European patent for its platform technology. This technology allows for precision nerve-targeted therapies specifically in the field of cardiology.

The granted patent underscores the company's innovative approach to medical device development, focusing on enhancing treatment precision for cardiac conditions.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time AMIX sparks.

Download Sniper App →

Catch the next AMIX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →